Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (OCS) announced the publication of a notification of transactions by a person discharging managerial responsibilities. The attached notification concerns the purchase of ordinary shares by a member of the company’s Executive Committee on June 10, 2026.
Oculis (Nasdaq:OCS) will present Privosegtor at Clinical Trials at the Summit 2026 in Las Vegas on June 13, 2026, at 5:52 PM PDT.
CEO Riad Sherif will discuss Privosegtor’s development from discovery through Phase 2 ACUITY to the PIONEER registrational trials in optic neuritis and other optic neuropathies.
Oculis (OCS)/b) published notifications on June 10, 2026 regarding transactions by persons discharging managerial responsibilities.The notifications concern the vesting and settlement of previously granted RSUs to company directors on June 6, 2026, including Arshad Khanani and Riad Sherif.
Oculis (OCS) announced the publication of a notification related to a managers' transaction on June 9, 2026 in Zug, Switzerland.
The attached notification concerns the purchase of ordinary shares by a member of the company’s Executive Committee and Board of Directors.
Oculis (Nasdaq: OCS) randomized the first patient in PREDICT-1, a genotype-based registrational trial of Licaminlimab for dry eye disease. The FDA-aligned study targets patients with a specific TNFR1 genotype to evaluate symptom relief and safety versus vehicle.
PREDICT-1 plans to enroll ~160 patients, with about two-thirds carrying the target genotype; ~70% of sites are activated. The trial aims to deliver a first-in-class precision medicine approach in a U.S. market where only ~13% of patients experience sustained relief.
Oculis (Nasdaq: OCS) will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 at 4:00 p.m. ET in Miami, FL.
Management will discuss late-stage assets Privosegtor and Licaminlimab, key trials, funding and upcoming pivotal readouts.
Oculis (NASDAQ:OCS) reported a notification of transactions by a person discharging managerial responsibilities. The notice concerns the vesting and settlement of RSUs previously granted to a company director on May 29, 2026.
Oculis (Nasdaq: OCS) reported topline Phase 3 DIAMOND-1 and DIAMOND-2 results for OCS-01 in diabetic macular edema. The primary BCVA endpoint and key ≥15-letter gain endpoint at Week 52 were not met.
Retinal thickness was substantially reduced vs vehicle, safety was consistent with prior trials, and no FDA filing in DME is planned. Oculis will prioritize its Privosegtor PIONEER optic neuropathy program and Licaminlimab PREDICT-1 dry eye trial, supported by $278 million in cash and runway into 2H 2029.
Oculis (OCS) announced a notification related to transactions by a person discharging managerial responsibilities. The attached document concerns the vesting and settlement of RSUs previously granted to a company director, identified as Arshad Khanani, with a vesting date of May 25, 2026.
Oculis (OCS) reported notifications of transactions by persons discharging managerial responsibilities. These relate to vesting and settlement of RSUs previously granted to directors, annual equity incentive awards to directors, and a one-time equity grant to a new director upon his election to the board.